The fibromyalgia treatment market size has grown steadily in recent years. It will grow from $2.89 billion in 2025 to $3.01 billion in 2026 at a compound annual growth rate (CAGR) of 4.2%. The growth in the historic period can be attributed to increased diagnosis of chronic pain disorders, availability of antidepressants and antiepileptics, rising healthcare access, expansion of pain clinics, improved disease awareness.
The fibromyalgia treatment market size is expected to see strong growth in the next few years. It will grow to $3.67 billion in 2030 at a compound annual growth rate (CAGR) of 5%. The growth in the forecast period can be attributed to development of targeted pain therapies, growth in personalized treatment plans, increased adoption of digital pain management tools, expansion of integrative therapies, rising mental health awareness. Major trends in the forecast period include rising use of symptom-based drug therapies, increased adoption of multimodal treatment approaches, growing focus on chronic pain management, expansion of non-pharmacological therapies, improved patient-centered care models.
The growth of the aging population is expected to contribute significantly to the expansion of the fibromyalgia treatment market. An aging population describes a demographic trend marked by a rising share of older individuals within a society. Fibromyalgia treatments are especially relevant for older adults, as this group is more prone to developing the condition and often experiences intensified symptoms due to age-related physiological changes. For example, in 2023, according to Age UK, a UK-registered charity, there were approximately 11 million people aged over 65 in England. This figure is projected to rise by 10% over the next five years and by 32% by 2043, representing increases of about 1.1 million and 3.5 million people, respectively. Additionally, the population aged 85 and above - those most likely to require health and social care services - is expected to grow rapidly, increasing by 8.2% within five years and by 62.7% by 2043, equivalent to around 126,000 and 956,000 people, respectively. Therefore, the expanding aging population is driving the growth of the fibromyalgia treatment market.
Leading players in the fibromyalgia treatment market are prioritizing the development of advanced technological solutions, including computerized behavioral therapy devices, to strengthen their competitive positioning. A computerized behavioral therapy device is a software-based, prescription digital treatment that delivers structured psychological interventions - such as Acceptance and Commitment Therapy (ACT) - through a digital platform. For instance, in May 2023, Swing Therapeutics, a US-based digital therapeutics company, received FDA De Novo authorization for Stanza, a prescription smartphone-based digital therapy that provides a 12-week, self-guided ACT program. In its pivotal PROSPER-FM Phase 3 trial, Stanza demonstrated meaningful improvements in pain, fatigue, sleep quality, and mood. The therapy is offered through Swing Care, a virtual specialty clinic that combines prescription digital therapeutics with comprehensive fibromyalgia care. This trend improves patient access, reduces dependence on pharmacological treatments, and supports guideline-recommended non-drug approaches, although challenges remain related to reimbursement scalability and clinician adoption.
In April 2023, XRHealth, a US-based telemedicine company offering fibromyalgia treatment solutions, merged with Amelia Virtual Care under the XRHealth brand. This merger enabled both organizations to consolidate into a single entity, allowing them to combine expertise, technologies, and operational resources. The integration brings together XRHealth’s immersive and augmented reality capabilities with Amelia Virtual Care’s advanced virtual reality software designed for mental health professionals. Amelia Virtual Care is a Spain-based company specializing in VR treatment solutions.
Major companies operating in the fibromyalgia treatment market are Pfizer Inc., Johnson and Johnson Services Inc., AbbVie Inc., Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Biogen Inc., Daiichi Sankyo Co. Ltd., Sun Pharmaceutical Industries Ltd., Horizon Therapeutics plc, Endo International plc, Amneal Pharmaceuticals Inc., Zydus Lifesciences Limited, Lupin Limited, Tonix Pharmaceuticals, Allergan plc, Aptinyx Inc., Novartis AG, Merck & Co Inc.
North America was the largest region in the fibromyalgia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fibromyalgia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the fibromyalgia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the fibromyalgia treatment market by raising prices for imported antidepressants, antiepileptics, muscle relaxants, and pharmaceutical active ingredients. Hospital pharmacies and retail pharmacies in Asia-Pacific and Latin America are most affected due to dependence on international drug manufacturers. These increased costs can elevate treatment expenses and reduce patient adherence. At the same time, tariffs are promoting domestic drug manufacturing, improving long-term supply stability.
The fibromyalgia treatment market research report is one of a series of new reports that provides fibromyalgia treatment market statistics, including fibromyalgia treatment industry global market size, regional shares, competitors with a fibromyalgia treatment market share, detailed fibromyalgia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the fibromyalgia treatment industry. This fibromyalgia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Fibromyalgia treatment involves the use of medications to manage fibromyalgia, a complex and chronic condition primarily characterized by widespread and often severe musculoskeletal pain, along with various associated symptoms. These treatments aim to reduce disease severity and help control the symptoms and complications related to the condition.
The main types of fibromyalgia treatment include symptomatic treatment and targeted treatment. Symptomatic treatment, also referred to as palliative or supportive care, focuses on alleviating individual symptoms and enhancing the patient’s overall quality of life. The different drug classes used include antidepressants, antiepileptics, muscle relaxants, analgesics, and others, which are distributed through multiple channels such as hospital pharmacies, retail pharmacies, and online pharmacies.
The fibromyalgia treatment market consists of revenues earned by providing medical diagnosis and evaluation, personalized treatment planning, medication management, pain management clinics and physical therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The fibromyalgia treatment market also includes sales of pain relievers, sleeping aids and anti-anxiety medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The fibromyalgia treatment market size is expected to see strong growth in the next few years. It will grow to $3.67 billion in 2030 at a compound annual growth rate (CAGR) of 5%. The growth in the forecast period can be attributed to development of targeted pain therapies, growth in personalized treatment plans, increased adoption of digital pain management tools, expansion of integrative therapies, rising mental health awareness. Major trends in the forecast period include rising use of symptom-based drug therapies, increased adoption of multimodal treatment approaches, growing focus on chronic pain management, expansion of non-pharmacological therapies, improved patient-centered care models.
The growth of the aging population is expected to contribute significantly to the expansion of the fibromyalgia treatment market. An aging population describes a demographic trend marked by a rising share of older individuals within a society. Fibromyalgia treatments are especially relevant for older adults, as this group is more prone to developing the condition and often experiences intensified symptoms due to age-related physiological changes. For example, in 2023, according to Age UK, a UK-registered charity, there were approximately 11 million people aged over 65 in England. This figure is projected to rise by 10% over the next five years and by 32% by 2043, representing increases of about 1.1 million and 3.5 million people, respectively. Additionally, the population aged 85 and above - those most likely to require health and social care services - is expected to grow rapidly, increasing by 8.2% within five years and by 62.7% by 2043, equivalent to around 126,000 and 956,000 people, respectively. Therefore, the expanding aging population is driving the growth of the fibromyalgia treatment market.
Leading players in the fibromyalgia treatment market are prioritizing the development of advanced technological solutions, including computerized behavioral therapy devices, to strengthen their competitive positioning. A computerized behavioral therapy device is a software-based, prescription digital treatment that delivers structured psychological interventions - such as Acceptance and Commitment Therapy (ACT) - through a digital platform. For instance, in May 2023, Swing Therapeutics, a US-based digital therapeutics company, received FDA De Novo authorization for Stanza, a prescription smartphone-based digital therapy that provides a 12-week, self-guided ACT program. In its pivotal PROSPER-FM Phase 3 trial, Stanza demonstrated meaningful improvements in pain, fatigue, sleep quality, and mood. The therapy is offered through Swing Care, a virtual specialty clinic that combines prescription digital therapeutics with comprehensive fibromyalgia care. This trend improves patient access, reduces dependence on pharmacological treatments, and supports guideline-recommended non-drug approaches, although challenges remain related to reimbursement scalability and clinician adoption.
In April 2023, XRHealth, a US-based telemedicine company offering fibromyalgia treatment solutions, merged with Amelia Virtual Care under the XRHealth brand. This merger enabled both organizations to consolidate into a single entity, allowing them to combine expertise, technologies, and operational resources. The integration brings together XRHealth’s immersive and augmented reality capabilities with Amelia Virtual Care’s advanced virtual reality software designed for mental health professionals. Amelia Virtual Care is a Spain-based company specializing in VR treatment solutions.
Major companies operating in the fibromyalgia treatment market are Pfizer Inc., Johnson and Johnson Services Inc., AbbVie Inc., Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Biogen Inc., Daiichi Sankyo Co. Ltd., Sun Pharmaceutical Industries Ltd., Horizon Therapeutics plc, Endo International plc, Amneal Pharmaceuticals Inc., Zydus Lifesciences Limited, Lupin Limited, Tonix Pharmaceuticals, Allergan plc, Aptinyx Inc., Novartis AG, Merck & Co Inc.
North America was the largest region in the fibromyalgia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fibromyalgia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the fibromyalgia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the fibromyalgia treatment market by raising prices for imported antidepressants, antiepileptics, muscle relaxants, and pharmaceutical active ingredients. Hospital pharmacies and retail pharmacies in Asia-Pacific and Latin America are most affected due to dependence on international drug manufacturers. These increased costs can elevate treatment expenses and reduce patient adherence. At the same time, tariffs are promoting domestic drug manufacturing, improving long-term supply stability.
The fibromyalgia treatment market research report is one of a series of new reports that provides fibromyalgia treatment market statistics, including fibromyalgia treatment industry global market size, regional shares, competitors with a fibromyalgia treatment market share, detailed fibromyalgia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the fibromyalgia treatment industry. This fibromyalgia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Fibromyalgia treatment involves the use of medications to manage fibromyalgia, a complex and chronic condition primarily characterized by widespread and often severe musculoskeletal pain, along with various associated symptoms. These treatments aim to reduce disease severity and help control the symptoms and complications related to the condition.
The main types of fibromyalgia treatment include symptomatic treatment and targeted treatment. Symptomatic treatment, also referred to as palliative or supportive care, focuses on alleviating individual symptoms and enhancing the patient’s overall quality of life. The different drug classes used include antidepressants, antiepileptics, muscle relaxants, analgesics, and others, which are distributed through multiple channels such as hospital pharmacies, retail pharmacies, and online pharmacies.
The fibromyalgia treatment market consists of revenues earned by providing medical diagnosis and evaluation, personalized treatment planning, medication management, pain management clinics and physical therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The fibromyalgia treatment market also includes sales of pain relievers, sleeping aids and anti-anxiety medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Fibromyalgia Treatment Market Characteristics
3. Fibromyalgia Treatment Market Supply Chain Analysis
4. Global Fibromyalgia Treatment Market Trends and Strategies
5. Fibromyalgia Treatment Market Analysis of End Use Industries
7. Global Fibromyalgia Treatment Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Fibromyalgia Treatment Total Addressable Market (TAM) Analysis for the Market
9. Fibromyalgia Treatment Market Segmentation
10. Fibromyalgia Treatment Market Regional and Country Analysis
11. Asia-Pacific Fibromyalgia Treatment Market
12. China Fibromyalgia Treatment Market
13. India Fibromyalgia Treatment Market
14. Japan Fibromyalgia Treatment Market
15. Australia Fibromyalgia Treatment Market
16. Indonesia Fibromyalgia Treatment Market
17. South Korea Fibromyalgia Treatment Market
18. Taiwan Fibromyalgia Treatment Market
19. South East Asia Fibromyalgia Treatment Market
20. Western Europe Fibromyalgia Treatment Market
21. UK Fibromyalgia Treatment Market
22. Germany Fibromyalgia Treatment Market
23. France Fibromyalgia Treatment Market
24. Italy Fibromyalgia Treatment Market
25. Spain Fibromyalgia Treatment Market
26. Eastern Europe Fibromyalgia Treatment Market
27. Russia Fibromyalgia Treatment Market
28. North America Fibromyalgia Treatment Market
29. USA Fibromyalgia Treatment Market
30. Canada Fibromyalgia Treatment Market
31. South America Fibromyalgia Treatment Market
32. Brazil Fibromyalgia Treatment Market
33. Middle East Fibromyalgia Treatment Market
34. Africa Fibromyalgia Treatment Market
36. Fibromyalgia Treatment Market Competitive Landscape and Company Profiles
37. Fibromyalgia Treatment Market Other Major and Innovative Companies
40. Fibromyalgia Treatment Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Fibromyalgia Treatment Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses fibromyalgia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for fibromyalgia treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The fibromyalgia treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Symptomatic Treatment; Targeted Treatment2) By Drug Class: Antidepressants; Antiepileptics; Muscle Relaxants; Analgesics; Other Drugs
3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
Subsegments:
1) By Symptomatic Treatment: Pain Relievers; Antidepressants; Anti-seizure Medications; Sleep Aids; Physical Therapy2) By Targeted Treatment: Cognitive Behavioral Therapy (CBT); Lifestyle Modifications; Complementary Therapies; Medications Targeting Specific Symptoms
Companies Mentioned: Pfizer Inc.; Johnson and Johnson Services Inc.; AbbVie Inc.; Eli Lilly and Company; Amgen Inc.; Viatris Inc.; Teva Pharmaceutical Industries Ltd.; Astellas Pharma Inc.; Biogen Inc.; Daiichi Sankyo Co. Ltd.; Sun Pharmaceutical Industries Ltd.; Horizon Therapeutics plc; Endo International plc; Amneal Pharmaceuticals Inc.; Zydus Lifesciences Limited; Lupin Limited; Tonix Pharmaceuticals; Allergan plc; Aptinyx Inc.; Novartis AG; Merck & Co Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Fibromyalgia Treatment market report include:- Pfizer Inc.
- Johnson and Johnson Services Inc.
- AbbVie Inc.
- Eli Lilly and Company
- Amgen Inc.
- Viatris Inc.
- Teva Pharmaceutical Industries Ltd.
- Astellas Pharma Inc.
- Biogen Inc.
- Daiichi Sankyo Co. Ltd.
- Sun Pharmaceutical Industries Ltd.
- Horizon Therapeutics plc
- Endo International plc
- Amneal Pharmaceuticals Inc.
- Zydus Lifesciences Limited
- Lupin Limited
- Tonix Pharmaceuticals
- Allergan plc
- Aptinyx Inc.
- Novartis AG
- Merck & Co Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 3.01 Billion |
| Forecasted Market Value ( USD | $ 3.67 Billion |
| Compound Annual Growth Rate | 5.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
